Skip to main content

Advertisement

SpringerLink
Log in

Clinical practice to address tamoxifen nonadherence

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The primary and secondary benefits of tamoxifen as adjuvant therapy in women with hormone-receptor-positive breast cancer are substantial: a 1% decrease in the risk of death each year for 10 years with each additional year of treatment during the first 5 years. Considerable data, however, indicate that these benefits are lost to many patients because of treatment nonadherence. Nonadherence is examined within the framework of the Common-Sense Model of Self-Regulation to describe patients’ models of disease and treatment that organize their thinking and behavior, and the crucial role of the practitioner in addressing and altering these models. Common patient education and social communications about patients’ hormone-receptor-positive breast cancer and tamoxifen treatment promote an acute disease paradigm in which cancer occurs within specific locations and is either present or absent. We recommend that clinicians communicate the concepts of hormone-receptor-positive breast cancer as follows: i. a non-dichotomous systemic disorder entailing a treatment goal of homeostasis and disease quiescence and ii. a disorder undetectable by currently available tests in subclinical states. Equally important, the clinician can provide a comprehensive picture of the well-documented secondary effects of tamoxifen, noting in particular the beneficial effects. Specific action plans, grounded in individual patient understanding, can be developed and reinforced, in an ongoing process that validates and integrates patient values and goals as they change over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Emanuel EJ (2017) Prescription for the future: the twelve transformational practices of highly effective medical organizations. Perseus Books, New York, p p219

    Google Scholar 

  2. World Health Organization (CH) (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva

    Google Scholar 

  3. https://en.wikipedia.org/wiki/Tamoxifen. Accessed 12 Sept 2020

  4. Leventhal H, Phillips LA, Burn E (2016) The common-sense model of self-regulation [CSM]: a dynamic framework for understanding illness self-management. J Behav Med 39(6):935–946. https://doi.org/10.1007/s10865-016-9782-2

    Article  PubMed  Google Scholar 

  5. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007 Mar 1) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109(5):832–839

    Article  CAS  Google Scholar 

  6. Ma AM, Barone J, Wallis AE et al (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4):500–504

    Article  Google Scholar 

  7. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ (2013) The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 109(5):1172–1180. https://doi.org/10.1038/bjc.2013.464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555

    Article  Google Scholar 

  9. Yood MU, Owusu C, Buist DS (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206(1):66–75

    Article  Google Scholar 

  10. Narod SA (2010) Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J Clin Oncol 28(33):e698–e699. https://doi.org/10.1200/JCO.2010.31.5770

    Article  CAS  PubMed  Google Scholar 

  11. van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851

    Article  Google Scholar 

  12. Hershman D, Shao T, Kushi L et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537

    Article  CAS  Google Scholar 

  13. Hershman DL, Kushi LH, Shao T et al (2012) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128

    Article  Google Scholar 

  14. Murphy C, Bartholomew LK, Carpentier M, Bluethmann S, Vernon S (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478

    Article  CAS  Google Scholar 

  15. Hadji P, Ziller V, Kyvernitakis J et al (2013) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 138(1):185–191

    Article  CAS  Google Scholar 

  16. Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325–328

    Article  Google Scholar 

  17. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524

    Article  CAS  Google Scholar 

  18. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000011

    Article  PubMed  Google Scholar 

  19. Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846

    Article  Google Scholar 

  20. Gray RG, Rea DW, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early stage breast cancer. J Clin Oncol 31(15_suppl):5. https://doi.org/10.1200/jco.2013.31.15_suppl.5

    Article  Google Scholar 

  21. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer. ATLAS, a randomized trial. Lancet 381:805–813

    Article  CAS  Google Scholar 

  22. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717

    Article  Google Scholar 

  23. National Comprehensive Care Network patient guidelines: invasive breast cancer [US][PDF] Accessed 4/9/20. https://www.nccn.org/patients/guidelines/content/PDF/breast-invasive-patient.pdf.

  24. Leventhal H, Nerenz D, Straus AM (1982) Self-regulation and the mechanisms for symptom appraisal. In: Mechanic D (ed) Monograph series in psychosocial epidemiology symptoms, illness behavior, and help seeking, vol 3. Neale Watson, New York, pp 55–86

    Google Scholar 

  25. Thomson AK, Heyworth JS, Girschik J, Sleven T, Saunders C, Fritschi L (2014) Beliefs and perceptions about the causes of breast cancer: a case control study. BMC Res Notes 7:558. https://doi.org/10.1186/1756-0500-7-558

    Article  PubMed  PubMed Central  Google Scholar 

  26. https://www.oxha.org/cih_manual/index.php/development-of-community-interventions-for-health-cih. Accessed 12 Sept 2020

  27. Phillips LA, Leventhal H, Leventhal EA (2012 May) Physicians’ communication of the common-sense self-regulation model results in greater reported adherence than physician’s use of interpersonal skills. Br J Health Psychol 17(2):244–257

    Article  Google Scholar 

  28. Baum M, Chaplain MA, Anderson AR, Douek M, Vaidya JS (1999) Does breast cancer exist in a state of chaos? Eur J Cancer 35(6):886–891

    Article  CAS  Google Scholar 

  29. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne E (2013) Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med 173(19):1830–1831. https://doi.org/10.1001/jamainternmed.2013.8405

    Article  PubMed  Google Scholar 

  30. Rosell J (2014) Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer. Linkoping University Electronic Press, Linkoping p 45 https://www.diva-portal.org/smash/get/diva2:763072/FULLTEXT02

  31. Khosrow-Khavar F, Filion KB, Al-Qurashi S et al (2017) Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 28:487–496

    Article  CAS  Google Scholar 

  32. Matthews A, Stanway S, Farmer RE et al (2018) Long-term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ 363:k3845. https://doi.org/10.1136/bmj.k3845

    Article  PubMed  PubMed Central  Google Scholar 

  33. Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial [P-1]. Ann NY Acad Sci 949:99–108

    Article  CAS  Google Scholar 

  34. Chen H, Liu H, Li J, Yang G (2015) Risk of gastric and colorectal cancer after tamoxifen use for breast cancer: a systematic review and meta-analysis. J Clin Gastroenterol 49(8):666–674. https://doi.org/10.1097/MCG.0000000000000262

    Article  CAS  PubMed  Google Scholar 

  35. Vogel VG (2009) The NSABP study of tamoxifen and raloxifene [STAR] trial. Expert Rev Anticancer Ther 9:51–60. https://doi.org/10.1586/14737140.9.1.51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Love RR, Mazess RB, Barden HSE et al (1992) Affects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856

    Article  CAS  Google Scholar 

  37. Love RR, Young GS, Laudico AV et al (2013) Bone mineral density changes following surgical oophorectomy and tamoxifen adjuvant therapy for operable breast cancer in pre-menopausal Filipino and Vietnamese women. Cancer 119:3746–3752

    Article  CAS  Google Scholar 

  38. Love RR, Wiebe DA, Newcomb PA et al (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860–864

    Article  CAS  Google Scholar 

  39. Tevaarwerk AJ, Wang M, Zhao F et al (2014) Phase III comparison tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node negative, hormone receptor positive breast cancer [E-3193, INT-0142]: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32(35):3948–3958. https://doi.org/10.1200/JCO.2014.55.6993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tanenbaum ML, Leventhal H, Breland JY, Yu J, Walker EA, Gonzalez JS (2015) Successful self-management among non-insulin-treated adults with type 2 diabetes: a self-regulation perspective. Diabet Med 32(11):1504–1512. https://doi.org/10.1111/dme.12745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bolman C, Arwert TG, Vollink T (2011) Adherence to prophylactic asthma medication: Habit strength and cognitions. Heart Lung 40(1):63–75. https://doi.org/10.1016/j.hrtlng.2010.02.003

    Article  PubMed  Google Scholar 

  42. Phillips LA, Leventhal H, Leventhal EA (2013) Assessing theoretical predictors of long-term medication adherence: patients’ treatment-related beliefs, experiential feedback and habit development. Psychol Health 28(10):1135–1151. https://doi.org/10.1080/08870446.2013.793798

    Article  Google Scholar 

Download references

Funding

This communication received no specific finding.

Author information

Authors and Affiliations

  1. Department of Computer Science, Marquette University, Milwaukee, WI, USA

    Richard R. Love

  2. University College, London, UK

    Michael Baum

  3. Dr. Susan Love Research Foundation, Encino, CA, USA

    Susan M. Love

  4. 2708 Columbia Road, Madison, WI, 53705, USA

    Andrea M. Straus

Authors
  1. Richard R. Love
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan M. Love
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea M. Straus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard R. Love.

Ethics declarations

Conflicts of interest

All authors report no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Love, R.R., Baum, M., Love, S.M. et al. Clinical practice to address tamoxifen nonadherence. Breast Cancer Res Treat 184, 675–682 (2020). https://doi.org/10.1007/s10549-020-05912-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-05912-y

Keywords

Search

Navigation